NCT05864144 - A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions

Solid Tumor, AdultAdvanced Solid TumorHead and Neck CancerBreast CancerColon CancerPancreatic CancerGastric CancerEsophageal CancerProstate CancerUterine CancerCervix CancerOvarian CancerKidney CancerBladder CancerThyroid CancerMelanomaSarcomaAdvanced CancerMetastatic CancerRefractory CancerNon Small Cell Lung CancerMerkel Cell Carcinoma

Interventions

DRUG

SNS-101 (anti-VISTA)

SNS-101 IV every 21 days.

DRUG

Cemiplimab

Cemiplimab IV every 21 days.

Trial Locations (10)

10029

Icahn School of Medicine at Mt. Sinai, New York

19104

University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia

40202

Norton Healthcare, Louisville

48202

Henry Ford Cancer, Detroit

57104

Sanford Cancer Center, Sioux Falls

75039

NEXT Oncology Dallas, Irving

78229

South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio

80045

University of Colorado Cancer Center - Anschutz Medical, Aurora

84119

START Mountain Region, West Valley City

90095

UCLA Hematology/Oncology, Los Angeles

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sensei Biotherapeutics, Inc.

INDUSTRY